BioRestorative Therapies, Inc.
BRTX
$1.57
-$0.04-2.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 240.40% | -28.57% | 124.35% | 660.91% | 38.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 240.40% | -28.57% | 124.35% | 660.91% | 38.14% |
| Cost of Revenue | 33.85% | -- | -- | -- | -- |
| Gross Profit | 256.66% | -36.86% | 107.25% | 601.63% | 28.06% |
| SG&A Expenses | 25.21% | 0.95% | -50.14% | -49.15% | -51.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.08% | 16.61% | -15.64% | -19.60% | -19.59% |
| Operating Income | -33.88% | -16.99% | 16.47% | 26.33% | 20.79% |
| Income Before Tax | 34.06% | -140.17% | 28.99% | -122.89% | 29.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.06% | -140.17% | 28.99% | -122.89% | 29.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.06% | -140.17% | 28.99% | -122.89% | 29.44% |
| EBIT | -33.88% | -16.99% | 16.47% | 26.33% | 20.79% |
| EBITDA | -34.34% | -16.95% | 16.94% | 26.89% | 21.27% |
| EPS Basic | 38.73% | -91.72% | 59.02% | -112.88% | 66.24% |
| Normalized Basic EPS | 38.74% | -91.69% | 101.89% | -112.88% | 66.24% |
| EPS Diluted | 38.73% | -91.72% | 58.90% | -112.92% | 66.26% |
| Normalized Diluted EPS | 38.74% | -91.69% | 101.89% | -112.88% | 66.24% |
| Average Basic Shares Outstanding | 7.62% | 25.27% | 73.34% | 77.68% | 108.98% |
| Average Diluted Shares Outstanding | 7.62% | 25.27% | 73.34% | 77.68% | 108.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |